Does the media prefer UTHR or DNTH?

In the previous week, United Therapeutics had 17 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 23 mentions for United Therapeutics and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.93 beat United Therapeutics' score of 0.88 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 13 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNTH or GMAB?

In the previous week, Dianthus Therapeutics and Dianthus Therapeutics both had 6 articles in the media. Dianthus Therapeutics' average media sentiment score of 0.93 beat Genmab A/S's score of 0.40 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DNTH or ASND?

In the previous week, Ascendis Pharma A/S had 9 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.93 beat Ascendis Pharma A/S's score of 0.88 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNTH or BBIO?

In the previous week, BridgeBio Pharma had 7 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.93 beat BridgeBio Pharma's score of 0.36 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EXEL or DNTH?

In the previous week, Exelixis had 21 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 27 mentions for Exelixis and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.93 beat Exelixis' score of 0.67 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 12 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Positive Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dianthus Therapeutics (DNTH) Competitors

$106.20 +2.92 (+2.83%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$104.99 -1.21 (-1.14%)

As of 09/11/2026 07:30 PM Eastern

Compare

DNTH vs. UTHR, GMAB, ASND, BBIO, and EXEL

Should you buy Dianthus Therapeutics stock or one of its competitors? Dianthus Therapeutics's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dianthus Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

United Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

United Therapeutics has a net margin of 41.56% compared to Dianthus Therapeutics' net margin of -10,096.95%. United Therapeutics' return on equity of 20.18% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

United Therapeutics currently has a consensus price target of $646.00, indicating a potential upside of 29.95%. Dianthus Therapeutics has a consensus price target of $129.83, indicating a potential upside of 22.25%. Given United Therapeutics' higher probable upside, analysts plainly believe United Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, United Therapeutics had 17 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 23 mentions for United Therapeutics and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.93 beat United Therapeutics' score of 0.88 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	13 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.70	$1.33B	$27.95	17.79
Dianthus Therapeutics	$2.04M	2,846.06	-$162.34M	-$4.15	N/A

Summary

United Therapeutics beats Dianthus Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Genmab A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Genmab A/S has a net margin of 19.08% compared to Dianthus Therapeutics' net margin of -10,096.95%. Genmab A/S's return on equity of 14.89% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Genmab A/S	19.08%	14.89%	7.73%

Dianthus Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

In the previous week, Dianthus Therapeutics and Dianthus Therapeutics both had 6 articles in the media. Dianthus Therapeutics' average media sentiment score of 0.93 beat Genmab A/S's score of 0.40 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,846.06	-$162.34M	-$4.15	N/A
Genmab A/S	$4.13B	4.90	$963M	$1.27	25.57

Dianthus Therapeutics currently has a consensus price target of $129.83, suggesting a potential upside of 22.25%. Genmab A/S has a consensus price target of $39.50, suggesting a potential upside of 21.65%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dianthus Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Dianthus Therapeutics beats Genmab A/S on 8 of the 15 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dianthus Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Dianthus Therapeutics presently has a consensus target price of $129.83, indicating a potential upside of 22.25%. Ascendis Pharma A/S has a consensus target price of $310.00, indicating a potential upside of 17.64%. Given Dianthus Therapeutics' higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05

In the previous week, Ascendis Pharma A/S had 9 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.93 beat Ascendis Pharma A/S's score of 0.88 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 70.99% compared to Dianthus Therapeutics' net margin of -10,096.95%. Ascendis Pharma A/S's return on equity of 32.54% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Dianthus Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,846.06	-$162.34M	-$4.15	N/A
Ascendis Pharma A/S	$814.57M	20.18	-$258M	$12.89	20.44

Summary

Ascendis Pharma A/S beats Dianthus Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Dianthus Therapeutics (NASDAQ:DNTH) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dianthus Therapeutics currently has a consensus target price of $129.83, indicating a potential upside of 22.25%. BridgeBio Pharma has a consensus target price of $102.61, indicating a potential upside of 41.65%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Dianthus Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,846.06	-$162.34M	-$4.15	N/A
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A

Dianthus Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 7 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.93 beat BridgeBio Pharma's score of 0.36 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma has a net margin of -97.03% compared to Dianthus Therapeutics' net margin of -10,096.95%. BridgeBio Pharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Summary

BridgeBio Pharma beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Exelixis has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Exelixis has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.71	$782.57M	$3.18	17.65
Dianthus Therapeutics	$2.04M	2,846.06	-$162.34M	-$4.15	N/A

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Exelixis had 21 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 27 mentions for Exelixis and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.93 beat Exelixis' score of 0.67 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	12 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Positive
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.33% compared to Dianthus Therapeutics' net margin of -10,096.95%. Exelixis' return on equity of 42.17% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Exelixis presently has a consensus target price of $50.07, suggesting a potential downside of 10.79%. Dianthus Therapeutics has a consensus target price of $129.83, suggesting a potential upside of 22.25%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Exelixis beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNTH vs. The Competition

Export

Metric	Dianthus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.65B	$3.84B	$7.14B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-25.59	14.25	275.24	25.29
Price / Sales	2,846.06	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	9.31	15.12	10.33	6.20
Net Income	-$162.34M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-1.76%	-4.34%	-3.32%	-2.35%
1 Month Performance	-5.52%	-0.02%	-0.41%	-2.77%
1 Year Performance	185.79%	40.64%	19.21%	7.63%

Dianthus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNTH Dianthus Therapeutics	2.1127 of 5 stars	$106.20 +2.8%	$129.83 +22.3%	+180.5%	$5.65B	$2.04M	N/A	92	Analyst Forecast Gap Up
UTHR United Therapeutics	4.2986 of 5 stars	$512.70 +0.5%	$646.00 +26.0%	+22.8%	$21.89B	$3.18B	18.34	1,400	Insider Trade
GMAB Genmab A/S	4.3603 of 5 stars	$33.29 +0.4%	$39.50 +18.7%	+13.5%	$20.68B	$3.72B	26.21	3,029
ASND Ascendis Pharma A/S	4.3814 of 5 stars	$260.25 -1.1%	$310.05 +19.1%	+33.3%	$16.41B	$814.57M	20.19	1,189	Analyst Forecast Insider Trade Analyst Revision
BBIO BridgeBio Pharma	3.4567 of 5 stars	$76.57 0.0%	$101.53 +32.6%	+37.7%	$14.97B	$502.08M	N/A	400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNTH) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. UTHR, GMAB, ASND, BBIO, and EXEL

How does Dianthus Therapeutics compare to United Therapeutics?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Summary

How does Dianthus Therapeutics compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. UTHR, GMAB, ASND, BBIO, and EXEL

How does Dianthus Therapeutics compare to United Therapeutics?

Which has more volatility & risk, UTHR or DNTH?

Do insiders & institutionals hold more shares of UTHR or DNTH?

Is UTHR or DNTH more profitable?

Do analysts rate UTHR or DNTH?

Does the media prefer UTHR or DNTH?

Which has stronger valuation and earnings, UTHR or DNTH?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Is DNTH or GMAB more profitable?

Which has more risk and volatility, DNTH or GMAB?

Does the media refer more to DNTH or GMAB?

Do insiders & institutionals have more ownership in DNTH or GMAB?

Which has preferable earnings and valuation, DNTH or GMAB?

Do analysts prefer DNTH or GMAB?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Do insiders & institutionals believe in DNTH or ASND?

Which has more volatility & risk, DNTH or ASND?

Do analysts rate DNTH or ASND?

Does the media refer more to DNTH or ASND?

Is DNTH or ASND more profitable?

Which has better valuation and earnings, DNTH or ASND?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Do institutionals & insiders believe in DNTH or BBIO?

Do analysts recommend DNTH or BBIO?

Which has preferable valuation and earnings, DNTH or BBIO?

Which has more volatility and risk, DNTH or BBIO?

Does the media refer more to DNTH or BBIO?

Is DNTH or BBIO more profitable?

Summary

How does Dianthus Therapeutics compare to Exelixis?

Which has more risk and volatility, EXEL or DNTH?

Which has higher valuation & earnings, EXEL or DNTH?

Do institutionals and insiders hold more shares of EXEL or DNTH?

Does the media prefer EXEL or DNTH?

Is EXEL or DNTH more profitable?

Do analysts rate EXEL or DNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools